JP2020534351A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534351A5 JP2020534351A5 JP2020534793A JP2020534793A JP2020534351A5 JP 2020534351 A5 JP2020534351 A5 JP 2020534351A5 JP 2020534793 A JP2020534793 A JP 2020534793A JP 2020534793 A JP2020534793 A JP 2020534793A JP 2020534351 A5 JP2020534351 A5 JP 2020534351A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cdr
- tm4sf1
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000014914 Carrier Proteins Human genes 0.000 claims description 85
- 108091008324 binding proteins Proteins 0.000 claims description 85
- 230000027455 binding Effects 0.000 claims description 80
- 239000012634 fragment Substances 0.000 claims description 75
- 239000000427 antigen Substances 0.000 claims description 67
- 102000036639 antigens Human genes 0.000 claims description 67
- 108091007433 antigens Proteins 0.000 claims description 67
- 101000658574 Homo sapiens Transmembrane 4 L6 family member 1 Proteins 0.000 claims description 54
- 102100034902 Transmembrane 4 L6 family member 1 Human genes 0.000 claims description 31
- 210000004027 cell Anatomy 0.000 claims description 25
- 102000055561 human TM4SF1 Human genes 0.000 claims description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 238000006467 substitution reaction Methods 0.000 claims description 11
- 230000035772 mutation Effects 0.000 claims description 10
- 101100225046 Schizosaccharomyces pombe (strain 972 / ATCC 24843) ecl2 gene Proteins 0.000 claims description 7
- 238000000684 flow cytometry Methods 0.000 claims description 7
- 230000037430 deletion Effects 0.000 claims description 5
- 238000012217 deletion Methods 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 210000002889 endothelial cell Anatomy 0.000 claims description 4
- 230000003993 interaction Effects 0.000 claims description 4
- 241000282567 Macaca fascicularis Species 0.000 claims description 3
- 230000013595 glycosylation Effects 0.000 claims description 3
- 238000006206 glycosylation reaction Methods 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 230000008614 cellular interaction Effects 0.000 claims description 2
- 210000000663 muscle cell Anatomy 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 238000009499 grossing Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 description 206
- 238000000034 method Methods 0.000 description 30
- 238000007822 cytometric assay Methods 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 8
- 206010027476 Metastases Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 230000009401 metastasis Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000013391 scatchard analysis Methods 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023033463A JP2023071888A (ja) | 2017-08-28 | 2023-03-06 | 抗ｔｍ４ｓｆ１抗体およびそれを使用する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762550994P | 2017-08-28 | 2017-08-28 | |
| US62/550,994 | 2017-08-28 | ||
| PCT/US2018/048402 WO2019046338A1 (en) | 2017-08-28 | 2018-08-28 | ANTI-TM4SF1 ANTIBODIES AND METHODS OF USE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023033463A Division JP2023071888A (ja) | 2017-08-28 | 2023-03-06 | 抗ｔｍ４ｓｆ１抗体およびそれを使用する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020534351A JP2020534351A (ja) | 2020-11-26 |
| JP2020534351A5 true JP2020534351A5 (enExample) | 2021-10-07 |
| JP7241080B2 JP7241080B2 (ja) | 2023-03-16 |
Family
ID=65526015
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020534793A Active JP7241080B2 (ja) | 2017-08-28 | 2018-08-28 | 抗ｔｍ４ｓｆ１抗体およびそれを使用する方法 |
| JP2023033463A Pending JP2023071888A (ja) | 2017-08-28 | 2023-03-06 | 抗ｔｍ４ｓｆ１抗体およびそれを使用する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023033463A Pending JP2023071888A (ja) | 2017-08-28 | 2023-03-06 | 抗ｔｍ４ｓｆ１抗体およびそれを使用する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11208495B2 (enExample) |
| EP (1) | EP3675906A4 (enExample) |
| JP (2) | JP7241080B2 (enExample) |
| CN (1) | CN111565750B (enExample) |
| AU (1) | AU2018323470B2 (enExample) |
| CA (1) | CA3074111A1 (enExample) |
| MX (1) | MX2020002241A (enExample) |
| WO (1) | WO2019046338A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016361503B2 (en) | 2015-11-24 | 2021-08-26 | Massachusetts Institute Of Technology | Systems and methods for preventing, mitigating, and/or treating dementia |
| KR102869711B1 (ko) | 2016-11-17 | 2025-10-15 | 코그니토 쎄라퓨틱스, 인코포레이티드 | 시각 자극을 통한 신경 자극 방법 및 시스템 |
| WO2019046338A1 (en) * | 2017-08-28 | 2019-03-07 | Angiex, Inc. | ANTI-TM4SF1 ANTIBODIES AND METHODS OF USE |
| CN111565698A (zh) | 2017-10-10 | 2020-08-21 | 麻省理工学院 | 用于预防、减轻和/或治疗痴呆的系统和方法 |
| WO2019241430A2 (en) * | 2018-06-12 | 2019-12-19 | Angiex, Inc. | Antibody-oligonucleotide conjugates |
| JP2022522007A (ja) * | 2019-02-27 | 2022-04-13 | アンジーエックス・インコーポレーテッド | 抗ｔｍ４ｓｆ１抗体を含む抗体薬物コンジュゲートおよびそれを使用する方法 |
| CN110734494B (zh) * | 2019-10-30 | 2021-04-30 | 上海市第一人民医院 | 抗tspan8单克隆抗体及其用途 |
| MX2022011958A (es) * | 2020-03-27 | 2023-01-11 | Angiex Inc | Conjugados de anticuerpo degradador y métodos de uso de los mismos. |
| WO2021222783A1 (en) * | 2020-05-01 | 2021-11-04 | Angiex, Inc. | Anti-tm4sf1 antibody drug conjugates and methods of using same |
| WO2022026915A2 (en) * | 2020-07-31 | 2022-02-03 | Angiex, Inc. | Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same |
| CA3213065A1 (en) * | 2021-03-26 | 2022-09-29 | Paul A. JAMINET | Maytansine-antibody conjugates and methods of using same |
| EP4313144A4 (en) * | 2021-03-26 | 2025-08-20 | Angiex Inc | COMBINATIONS COMPRISING ANTI-TM4SF1 ANTIBODIES AND IMMUNOTHERAPY AGENTS AND METHODS OF USE THEREOF |
| WO2022255401A1 (ja) * | 2021-06-03 | 2022-12-08 | 国立大学法人 東京大学 | Ｅｒｋ－ｍａｐｋ経路の異常な活性化に伴い発現する疾患マーカー |
| WO2022255843A1 (ko) * | 2021-06-03 | 2022-12-08 | 주식회사 메드팩토 | Tm4sf19 억제제 및 이의 용도 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| ATE531812T1 (de) | 1997-12-05 | 2011-11-15 | Scripps Research Inst | Humanisierung von nager-antikörpern |
| DK1068241T3 (da) | 1998-04-02 | 2008-02-04 | Genentech Inc | Antistofvarianter og fragmenter deraf |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US20040214872A1 (en) | 2002-09-26 | 2004-10-28 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| WO2005097832A2 (en) | 2004-03-31 | 2005-10-20 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| DK2175884T3 (en) | 2007-07-12 | 2016-09-26 | Gitr Inc | Combination USING GITR BINDING MOLECULES |
| PL2250279T3 (pl) | 2008-02-08 | 2016-11-30 | Przeciwciała anty-ifnar1 o zmniejszonym powinowactwie do liganda fc | |
| WO2010073694A1 (ja) * | 2008-12-25 | 2010-07-01 | 国立大学法人東京大学 | 抗tm4sf20抗体を用いた癌の診断と治療 |
| SI2691417T2 (sl) | 2011-03-29 | 2025-05-30 | Roche Glycart Ag | FC variante protitelesa |
| JP6152090B2 (ja) | 2011-04-21 | 2017-06-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ | 視神経脊髄炎を処置するための組成物および方法 |
| CN102590531A (zh) * | 2012-03-24 | 2012-07-18 | 广西壮族自治区肿瘤防治研究所 | 卵巢癌相关抗原自身抗体谱液相芯片检测试剂盒及其制备方法 |
| WO2015054427A1 (en) * | 2013-10-10 | 2015-04-16 | Beth Israel Deaconess Medical Center, Inc. | Tm4sf1 binding proteins and methods of using same |
| KR102367876B1 (ko) | 2013-11-22 | 2022-02-24 | 사브레 테라퓨틱스 엘엘씨 | 오토탁신 억제제 화합물 |
| SG10201912986PA (en) | 2014-05-28 | 2020-02-27 | Agenus Inc | Anti-gitr antibodies and methods of use thereof |
| WO2019046338A1 (en) * | 2017-08-28 | 2019-03-07 | Angiex, Inc. | ANTI-TM4SF1 ANTIBODIES AND METHODS OF USE |
-
2018
- 2018-08-28 WO PCT/US2018/048402 patent/WO2019046338A1/en not_active Ceased
- 2018-08-28 AU AU2018323470A patent/AU2018323470B2/en active Active
- 2018-08-28 CA CA3074111A patent/CA3074111A1/en active Pending
- 2018-08-28 EP EP18849908.1A patent/EP3675906A4/en active Pending
- 2018-08-28 JP JP2020534793A patent/JP7241080B2/ja active Active
- 2018-08-28 CN CN201880070504.7A patent/CN111565750B/zh active Active
- 2018-08-28 MX MX2020002241A patent/MX2020002241A/es unknown
- 2018-08-28 US US16/642,995 patent/US11208495B2/en active Active
-
2021
- 2021-11-22 US US17/532,660 patent/US20220267461A1/en not_active Abandoned
- 2021-11-22 US US17/532,664 patent/US20220153860A1/en not_active Abandoned
-
2023
- 2023-03-06 JP JP2023033463A patent/JP2023071888A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020534351A5 (enExample) | ||
| CA2987118C (en) | A pdl-1 antibody, pharmaceutical composition thereof and use thereof | |
| IL293241A (en) | Bispecific antibody, anti-1-pd, anti-vegfa, pharmaceutical preparation containing it and its use | |
| JP2016514676A (ja) | 四価二重特異性抗体 | |
| JP2025506318A (ja) | 抗ｔｉｇｉｔ抗体と抗ｐｄ－１－抗ｖｅｇｆａ二重特異性抗体を含有する医薬組成物及び使用 | |
| US20230052369A1 (en) | Antibody constructs binding 4-1bb and tumor-associated antigens and uses thereof | |
| CN112166125B (zh) | 全人源的抗lag-3抗体及其应用 | |
| CA3228641A1 (en) | Fap/cd40 binding molecule and medicinal use thereof | |
| KR20210027254A (ko) | Tim-3에 대한 항체 및 그의 용도 | |
| JPWO2021104302A5 (enExample) | ||
| JPWO2021019389A5 (enExample) | ||
| US20230340119A1 (en) | Composition of triax antibodies and method of making and using thereof | |
| CN114269784A (zh) | 具有选择性可切割接头的双特异性结合构建体 | |
| JPWO2021213475A5 (enExample) | ||
| US20230265202A1 (en) | Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof | |
| JPWO2019170885A5 (enExample) | ||
| CN116783217A (zh) | 具有多个结合结构域的免疫球蛋白构建体 | |
| JPWO2023051683A5 (enExample) | ||
| JPWO2023026236A5 (enExample) | ||
| WO2024141049A1 (zh) | 抗ox40抗体及其应用 | |
| TW202535936A (zh) | 靶向liv-1之抗體及其用途 | |
| RU2024107310A (ru) | Радиоконъюгаты к psma и способы их применения | |
| JPWO2022010847A5 (enExample) | ||
| WO2025157267A1 (zh) | 抗pd-1-抗vegfa的双特异性抗体的医药用途 | |
| TW202506193A (zh) | Trop2結合劑及其結合物 |